Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades. The most ...
Revenue (in standard metal prices) is expected to be approximately EUR 2.63-2.78bn, and operational EBITDA is expected to be approximately EUR 360-410m. In 2025, NKT achieved revenue (in standard ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant ...
NKT has finalized contracts with SSEN Transmission for two high-voltage direct-current (HVDC) transmission links in Scotland, the company announced January 19. The projects, valued at approximately €2 ...
To support the high demand for high-voltage power cable accessories in Europe, NKT has invested in the construction of a new test hall, the expansion of production capacity, and a new office building ...
Scientists at UCLA have developed an “off-the-shelf” cell-based immunotherapy that was able to track down and kill pancreatic cancer cells even after they had spread to other organs. In a mouse study, ...
Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers ...
Welcome to NKT Interim Report for Q3 2023 Presentation. Today's call is being recorded [Operator Instructions] I would now like to introduce President and CEO, Claes Westerlind; and CFO, Line Andrea ...
Investing.com -- NKT (CSE:NKT) shares jumped more than 13% on Wednesday after the Denmark-based cable manufacturer reported third-quarter results that exceeded expectations and announced new financial ...
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful ...
AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results